PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRubidium
Rubidium rb-82
Cardiogen, Ruby-fill (rubidium rb-82) is a small molecule pharmaceutical. Rubidium rb-82 was first approved as Cardiogen-82 on 1989-12-29.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
cardiogen-82New Drug Application2024-06-12
ruby-fillNew Drug Application2020-10-20
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09G: Cardiovascular system diagnostic radiopharmaceuticals
— V09GX: Other cardiovascular system diagnostic radiopharmaceuticals in atc
— V09GX04: Rubidium (82rb) chloride
HCPCS
Code
Description
A9555
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries
Clinical
Clinical Trials
20 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.11—12812
Myocardial ischemiaD017202EFO_1001375I20-I251—1147
Myocardial infarctionD009203EFO_0000612I211——113
InfarctionD007238EFO_0009463—1——113
Coronary diseaseD003327————1113
Heart failureD006333HP_0001635I50———1—1
HypertensionD006973EFO_0000537I10———1—1
Pulmonary hypertensionD006976EFO_0001361I27.20———1—1
CardiomyopathiesD009202EFO_0000318I42———1—1
Pulmonary arterial hypertensionD000081029—————1—1
Show 3 more
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart diseasesD006331EFO_0003777I51.92———46
SarcoidosisD012507EFO_0000690D80-D891————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Radiation exposureD000069079——————22
Left ventricular dysfunctionD018487——————11
Colorectal neoplasmsD015179——————11
Breast neoplasmsD001943EFO_0003869C50————11
Head and neck neoplasmsD006258——————11
Esophageal neoplasmsD004938—C15————11
Lung neoplasmsD008175HP_0100526C34.90————11
Myocardial reperfusionD015425——————11
IschemiaD007511EFO_0000556—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRubidium rb-82
INN—
Description
Cardiogen, Ruby-fill (rubidium rb-82) is a small molecule pharmaceutical. Rubidium rb-82 was first approved as Cardiogen-82 on 1989-12-29.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
[82Rb]
Identifiers
PDB—
CAS-ID14391-63-0
RxCUI—
ChEMBL IDCHEMBL4297424
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 116 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cardiogen-82, Ruby-fill
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
135 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use